세포 흡인 검사에서 Peptide Nucleic Acid-Mediated PCR Clamping법을 이용한 BRAFV600E 유전자 변이 검사
Detection of BRAFV600E Mutation using Peptide Nucleic Acid-Mediated PCR Clamping Method in Fine Needle Aspiration Cytology
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the diagnostic value of a peptide nucleic acid (PNA)-mediated PCR clamping method for the detection of BRAFV600E mutations in fine needle aspiration cytology (FNAC). Methods: One hundred sixty four patients underwent FNAC to evaluate BRAFV600E mutations between April 2011 and November 2011. Among them, forty-two patients were diagnosed with papillary thyroid carcinoma in a permanent pathologic specimen. A PNA-mediated PCR clamping method and a Dual-Priming Oligonucleotide (DPO)-based Real-time PCR method were used to detect the BRAFV600E mutation. We compared the result of mutation between the two methods. Results: A BRAF mutation was found in 31 samples created by the PNA-mediated PCR clamping method, and in 28 samples in the DPO-based Real-time PCR method. The rate of BRAF mutation was 73.8% in association with the PNA-mediated PCR clamping method, and 66.7% in association with the DPO-based Real-time PCR method. There was no statistical differences between the two methods (P＞0.05). Conclusion: The PNA-mediated PCR clamping method may be an alternative to the DPO-based Real-Time PCR method for detection of BRAF mutations in thyroid nodules.
Abstract
Purpose: The aim of this study was to evaluate the diagnostic value of a peptide nucleic acid (PNA)-mediated PCR clamping method for the detection of BRAFV600E mutations in fine needle aspiration cytology (FNAC). Methods: One hundred sixty four patients underwent FNAC to evaluate BRAFV600E mutations between April 2011 and November 2011. Among them, forty-two patients were diagnosed with papillary thyroid carcinoma in a permanent pathologic specimen. A PNA-mediated PCR clamping method and a Dual-Priming Oligonucleotide (DPO)-based Real-time PCR method were used to detect the BRAFV600E mutation. We compared the result of mutation between the two methods. Results: A BRAF mutation was found in 31 samples created by the PNA-mediated PCR clamping method, and in 28 samples in the DPO-based Real-time PCR method. The rate of BRAF mutation was 73.8% in association with the PNA-mediated PCR clamping method, and 66.7% in association with the DPO-based Real-time PCR method. There was no statistical differences between the two methods (P＞0.05). Conclusion: The PNA-mediated PCR clamping method may be an alternative to the DPO-based Real-Time PCR method for detection of BRAF mutations in thyroid nodules.
참고문헌 (17)
- Weiss RE, "Thyroid nodules: diagnosis and therapy", Curr Opin Oncol, 14, pp.46~52 (2002)
- Annual report of cancer incidence (2007), cancer prevalence (2007) and survival (1993-2007) in Korea, "Ministry for Health, Welfare and Family Affairs", Ministry for Health, Welfare and Family Affairs, ~ (2009)
- Hamacher C, "Expression of functional stimulatory guanine nucleotide binding protein in nonfunctioning thyroid adenomas is not correlated to adenylate cyclase activity and growth of these tumors", J Clin Endocrinol Metab, 80, pp.1724~1732 (1995)
- Fusco A, "A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases", Nature, 328, pp.170~172 (1987)
- Feinstein E, "Expression of the normal p53 gene induces differentiation of K562 cells", Oncogene, 7, pp.1853~1857 (1992)
- Frasca F, "BRAF(V600E) mutation and the biology of papillary thyroid cancer", Endocr Relat Cancer, 15, pp.191~205 (2008)
- Kim SK, "Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules", Diagn Mol Pathol, 17, pp.118~125 (2008)
- Lee HJ, "Detection of BRAF mutations in thyroid nodules by allele- specific PCR using a dual priming oligonucleotide system", Am J Clin Pathol, 133, pp.802~808 (2010)
- Kwak JY, "Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area", Head Neck, 32, pp.490~498 (2010)
- Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
- Sala E, "BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells", Mol Cancer Res, 6, pp.751~759 (2008)
- Flaherty KT, "Mutation-driven drug development in melanoma", Curr Opin Oncol, 22, pp.178~183 (2010)
- Frasca F, "BRAF(V600E) mutation and the biology of papillary thyroid cancer", Endocr Relat Cancer, 15, pp.191~205 (2008)
- Kebebew E, "The prevalence and prognostic value of BRAF mutation in thyroid cancer", Ann Surg, 246, pp.466~470 (2007)
- Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90, pp.6373~6379 (2005)
- Lee X, "Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma", Ann Surg Oncol, 16, pp.240~245 (2009)
- Puxeddu E, "BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas", J Clin Endocrinol Metab, 89, pp.2414~2420 (2004)